Compare BNED & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNED | CMPX |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 408.8M |
| IPO Year | 2015 | 2020 |
| Metric | BNED | CMPX |
|---|---|---|
| Price | $12.16 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 194.9K | ★ 2.9M |
| Earning Date | 03-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.60 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,714,770,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | $24.74 | ★ N/A |
| Revenue Growth | ★ 6.50 | N/A |
| 52 Week Low | $5.90 | $1.61 |
| 52 Week High | $14.75 | $6.88 |
| Indicator | BNED | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 52.28 |
| Support Level | $11.56 | $1.82 |
| Resistance Level | $13.09 | $2.51 |
| Average True Range (ATR) | 0.48 | 0.13 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 39.11 | 42.86 |
Barnes & Noble Education Inc is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also a textbook wholesaler and inventory management hardware and software provider. It offers course materials through physical and online bookstores, including new and used print textbooks, rental options, digital textbooks, and publisher-hosted digital courseware. Products are also offered directly to students through Textbooks.com. The majority of the company's revenue is derived from the sale of products through its bookstore locations, including virtual bookstores, and the bookstore affiliated e-commerce websites.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.